PriceTargets.com logo

Knight Therapeutics - GUD Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$6.98
  • Forecasted Upside: 15.29%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
C$6.05 As of 12/4/2025 05:00 PM ET
▲ +0.01 (0.17%)

This chart shows the closing price for GUD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Knight Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GUD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GUD

Analyst Price Target is C$6.98
▲ +15.29% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Knight Therapeutics in the last 3 months. The average price target is C$6.98, with a high forecast of C$7.45 and a low forecast of C$6.50. The average price target represents a 15.29% upside from the last price of C$6.05.

This chart shows the closing price for GUD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Knight Therapeutics. This rating has held steady since August 2025, when it changed from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 2 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/9/2025Canaccord Genuity GroupSet TargetHold ➝ BuyC$6.50
3/25/2025Stifel NicolausBoost TargetBuyC$6.25 ➝ C$7.45
3/21/2025Canaccord Genuity GroupDowngradeStrong-Buy ➝ Hold
3/11/2025Research CapitlUpgradeHold ➝ Strong-Buy
11/15/2024Raymond James FinancialUpgradeModerate Buy
11/14/2024Raymond James FinancialLower TargetC$8.00 ➝ C$7.50
8/13/2024Stifel NicolausUpgradeHold ➝ BuyC$5.75 ➝ C$6.75
8/12/2024Stifel CanadaUpgradeHold ➝ Strong-Buy
5/10/2024Stifel NicolausBoost TargetC$5.40 ➝ C$5.75
5/1/2024Stifel NicolausBoost TargetHoldC$5.25 ➝ C$5.40
3/22/2024Royal Bank Of CanadaBoost TargetOutperformC$6.50 ➝ C$7.00
3/6/2024Raymond James FinancialBoost TargetOutperformC$7.00 ➝ C$7.50
2/28/2024Raymond James FinancialSet TargetOutperformC$7.00
11/10/2023Stifel NicolausLower TargetC$5.40 ➝ C$5.25
3/24/2023National Bank FinancialDowngradeOutperform Market Weight ➝ Sector Perform Market Weight
3/24/2023National BanksharesLower TargetOutperform ➝ Sector PerformC$7.75 ➝ C$6.00
3/24/2023Royal Bank Of CanadaLower TargetOutperformC$7.50 ➝ C$6.50
8/12/2022Stifel NicolausBoost TargetC$5.30 ➝ C$5.40
8/12/2022National BanksharesBoost TargetOutperformC$7.50 ➝ C$7.75
4/1/2022Raymond James FinancialSet TargetOutperformC$7.50
3/28/2022Bloom BurtonReiterated RatingBuyC$6.70
3/25/2022Bloom BurtonDowngradeBuy ➝ Accumulate
3/25/2022National Bank FinancialLower TargetOutperformC$8.00 ➝ C$7.50
3/25/2022Raymond James FinancialLower TargetOutperformC$8.50 ➝ C$7.50
3/25/2022Canaccord Genuity GroupLower TargetC$8.00 ➝ C$7.00
3/25/2022National BanksharesLower TargetOutperformC$8.00 ➝ C$7.50
3/24/2022Stifel NicolausDowngradeHoldC$5.30
11/12/2021Raymond James FinancialSet TargetOutperformC$8.50
11/12/2021National BanksharesBoost TargetOutperformC$7.75 ➝ C$8.00
9/24/2021Raymond James FinancialReiterated RatingOUTPERFORMC$8.50
9/22/2021Stifel NicolausUpgradeBuyC$6.50
8/17/2021Raymond James FinancialReiterated RatingOutperformC$8.50
7/13/2021Royal Bank Of CanadaReiterated RatingOutperformC$7.50
5/17/2021Raymond James FinancialReiterated RatingOutperformC$8.50
4/26/2021National Bank FinancialBoost TargetOutperformC$7.75
4/26/2021National BanksharesBoost TargetOutperformC$6.75 ➝ C$7.75
4/26/2021Raymond James FinancialBoost TargetOutperformC$8.00 ➝ C$8.50
3/26/2021Bloom BurtonUpgradeAccumulate ➝ Buy
3/26/2021Raymond James FinancialReiterated RatingOutperformC$8.00
3/25/2021National Bank FinancialReiterated RatingOutperform Market Weight
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.48 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Knight Therapeutics logo
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.
Read More

Today's Range

Now: C$6.05
Low: C$6.04
High: C$6.09

50 Day Range

MA: C$5.94
Low: C$5.75
High: C$6.24

52 Week Range

Now: C$6.05
Low: C$5.11
High: C$6.55

Volume

20,473 shs

Average Volume

60,403 shs

Market Capitalization

C$600.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.011772

Frequently Asked Questions

What sell-side analysts currently cover shares of Knight Therapeutics?

The following Wall Street sell-side analysts have issued reports on Knight Therapeutics in the last twelve months: Canaccord Genuity Group Inc., Research Capitl, and Stifel Nicolaus.
View the latest analyst ratings for GUD.

What is the current price target for Knight Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Knight Therapeutics in the last year. Their average twelve-month price target is C$6.98, suggesting a possible upside of 15.3%. Stifel Nicolaus has the highest price target set, predicting GUD will reach C$7.45 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of C$6.50 for Knight Therapeutics in the next year.
View the latest price targets for GUD.

What is the current consensus analyst rating for Knight Therapeutics?

Knight Therapeutics currently has 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GUD will outperform the market and that investors should add to their positions of Knight Therapeutics.
View the latest ratings for GUD.

What other companies compete with Knight Therapeutics?

Other companies that are similar to Knight Therapeutics include Cronos Group, Hydropothecary, DRI Healthcare Trust, Canopy Growth and Cipher Pharmaceuticals. Learn More about companies similar to Knight Therapeutics.

How do I contact Knight Therapeutics' investor relations team?

Knight Therapeutics' physical mailing address is 3400 de Maisonneuve Boulevard West, Suite 1055, Montreal, QC H3Z 3B8, Canada. The company's listed phone number is 514-484-4483. The official website for Knight Therapeutics is www.gud-knight.com. Learn More about contacing Knight Therapeutics investor relations.